| HOME >> BIOLOGY >> TECHNOLOGY |
SOUTH SAN FRANCISCO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- VaxGen Inc. (Pink Sheets: VXGN) today announced further cost-cutting measures consistent with its continuing commitment to align its cost structure with its pursuit of strategic initiatives.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)
VaxGen is reducing its workforce from 61 to 27 employees, which the company expects will lower its monthly cash expenditures used in operating activities to $1.4 million. The company will incur a restructuring charge of approximately $1.1 million in connection with this action. The terminations include executive officer Lance Ignon, Vice President of Corporate Affairs.
This is VaxGen's third restructuring since the U.S. Department of Health and Human Services (HHS) cancelled the company's contract to provide a modern anthrax vaccine for civilian biodefense in December 2006.
"Throughout this year we have retained only those resources that management felt could build value for our shareholders, either because they enhanced our ability to complete a strategic transaction or they were required to meet essential business objectives," said James P. Panek, VaxGen's President and CEO. "Based on our understanding of the nature and structure of such potential transactions, we are now able to take this further restructuring action. We remain optimistic about completing a strategic transaction and are in various stages of discussions with a variety of companies."
VaxGen has retained key resources necessary to support its pursuit of
strategic transactions, including key scientific personnel for technical
due diligence. The company has also retained people associated with the
company's financial reporting obligations to the Securities and Exchange
Commission. "These are not easy decisions, especially when you are talking
about letting go of many ta
'/>"/>
| SOURCE VaxGen, Inc. Copyright©2007 PR Newswire. All rights reserved |